Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Breast 1

Conditions

Interventions

Surveys and Questionnaires 65 pembrolizumab 56 Gemcitabine 54 Paclitaxel 51 Blood Specimen Collection 45 Carboplatin 44 Bevacizumab 41 Docetaxel 38 Cisplatin 33 Nivolumab 32 Fluorouracil 31 Capecitabine 28 Radiotherapy 25 Pemetrexed 25 Irinotecan 25 Standard of Care 24 Interviews as Topic 24 Magnetic Resonance Spectroscopy 23 Leucovorin 22 Erlotinib Hydrochloride 22 atezolizumab 21 Cetuximab 21 Afatinib 21 Oxaliplatin 19 trametinib 18 Exercise 18 Ipilimumab 17 Sorafenib 16 Cyclophosphamide 16 olaparib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × patritumab deruxtecan × Tumor-Agnostic × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡